Ritonavir
What's New
Last Posted: Aug 23, 2023
- MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY.
Jon Salmanton-García, et al. International journal of antimicrobial agents 2023 0 106952 - Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
Julie Bertrand, et al. Antimicrobial agents and chemotherapy 2023 0 e0233918 - Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama Kazuaki, et al. Journal of gastroenterology 2017 0 (4) 557-565 - HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
Lathouwers Erkki, et al. HIV clinical trials 2017 0 (5-6) 196-204 - HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
Hoppe Anne, et al. Antiviral therapy 2017 0 (2) 191-195 - Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele.
Panagopoulos Periklis, et al. Pharmacogenomics and personalized medicine 2017 0 205-208 - Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Kulkarni Rima, et al. HIV clinical trials 2017 0 (4) 164-173 - The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Janczewska Ewa, et al. BMC infectious diseases 2018 0 (1) 580 - Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study.
Itokawa Norio, et al. Hepatology research : the official journal of the Japan Society of Hepatology 2018 0 (2) 125-135 - Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
Hsieh Yi-Chung, et al. PloS one 2018 0 (8) e0202777
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 27, 2024
- Content source: